Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
FCBC$47.50+0.05(+0.11%)First Community Bankshares, Inc. Announces Acquisition of Main Street Financial Services Corp.[8:17:00 AM ET]BEN$31.39+0.40(+1.29%)ChinaAMC and Franklin Templeton Sign Strategic MOU to Deepen Cross-Border Collaboration China Asset Management Co., Ltd. (ChinaAMC) and Franklin Templeton today announced in Shenzhen, China, the signing of a strategic Memorandum of...[8:17:00 AM ET]AGCO$103.40-0.81(-0.78%)AGCO Names Georgia Educator Ben Brand Inaugural Ag Mechanics Teacher of the Year AGCO (NYSE: AGCO) named Ben Brand of Social Circle High School in Social Circle, Georgia, the inaugural Agricultural Mechanics Teacher of the Year....[8:15:00 AM ET]MDA$29.30+0.03(+0.10%)49North Qualifies Across All Five Streams of Canada's Defence Drone Initiative Marketplace 49North, a wholly owned subsidiary of MDA Space Ltd. (TSX: MDA) (NYSE: MDA), today announced that it has qualified across all five streams of...[8:15:00 AM ET]GREH$0.01+0.00(+2.30%)Green Rain Energy Holdings Highlights Three Completed EV Charging Projects in New York and California, Looks Ahead to Continued Expansion[8:15:00 AM ET]INFY$11.91-0.20(-1.62%)Canada's UNI Financial Cooperation Advances Branch Modernization with Infosys Finacle Universal Banker Infosys Finacle, part of EdgeVerve Systems, a wholly owned subsidiary of Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), and UNI Financial Cooperation...[8:14:00 AM ET]CYMHF$0.07+0.01(+14.90%)KAP MINERALS AND CYMAT TECHNOLOGIES ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP CANADIAN SCANDIUM-ALUMINUM MASTER ALLOY PRODUCTION KAP Minerals Inc. ("KAP") and Cymat Technologies Ltd. (TSXV: CYM) (OTCQB: CYMHF) ("Cymat") are pleased to announce the signing of a Memorandum of...[8:10:00 AM ET]GEVO$1.18+0.01(+0.85%)Gevo Announces Appointment of K’Lynne Johnson to Board of Directors[8:10:00 AM ET]MXCT$1.57+0.03(+1.95%)MaxCyte to Participate in Three Upcoming Investor Conferences[8:05:00 AM ET]TDTH$0.57-0.03(-4.51%)Trident Founder & CEO to Buy Up to 1,000,000 Shares in the Open Market[8:05:00 AM ET]MTOPF$0.020.00(0.00%)Barbrook Gold Mine Business Rescue Plan is Advancing - Lions Bay Resources Corrects Misleading Vantage Goldfield Claims[8:04:00 AM ET]AMTX$1.29-0.02(-1.53%)Aemetis to Review Third Quarter 2026 Financial Results on November 5, 2026[8:03:22 AM ET]SATL$4.00+0.05(+1.25%)Satellogic Schedules Third Quarter 2026 Results Conference Call on Tuesday, November 10, 2026, at 4:30 p.m. Eastern Time[8:00:00 AM ET]BA$168.60+0.42(+0.25%)Boeing: Global Freighter Fleet to Exceed 4,000 Airplanes as Air Cargo Traffic Doubles by 2045 Boeing [NYSE: BA] projects in its 2026 World Air Cargo Forecast that air cargo traffic will double over the next 20 years, driving the freighter...[8:00:00 AM ET]BCAL$21.59-0.36(-1.64%)CALIFORNIA BANCORP REPORTS THIRD QUARTER EARNINGS, HIGHLIGHTED BY STEADY LOAN GROWTH AND STRONG DEPOSIT GROWTH[8:00:00 AM ET]

QURE · NASDAQ

uniQure N.V.

$24.33 +0.09 (+0.37%)

Company overview

uniQure N.V. is a gene therapy company focused on developing treatments for patients with genetic and other devastating diseases. Its lead program is etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for hemophilia B. The company is also developing AMT-130, a gene therapy in Phase I/II clinical study for Huntington's disease; AMT-060, in Phase I/II clinical trial for hemophilia B; AMT-210 for Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical candidate for autosomal dominant Alzheimer's disease; and AMT-161 for amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.7B
Employees
209
Headquarters
Amsterdam
Website
uniqure.com
CEO
Matthew Craig Kapusta
Listed
February 5, 2014
P/E
-6.93
Dividend yield
0.00%

Company financials

Revenue
$18.1M
Gross profit
$13.4M
Operating income
-$191M
EBITDA
-$155M
Net income
-$209M
EPS
-$3.51
Total assets
$779M
Total debt
$63.3M
Gross margin
74.14%
Net margin
-1,154.42%
Earnings yield
-14.43%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

15.2024.6834.1643.6453.12
QURE 1D NASDAQ O21.76H24.24L21.51C24.24+2.59 (+11.96%)Vol471.86K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
QUREuniQure N.V. Press release uniQure to Announce Third Quarter 2026 Financial Results GlobeNewswire
QUREuniQure N.V. Legal Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Shareholders to Connect ACCESS Newswire
QUREuniQure N.V. Legal Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against uniQure N.V. (QURE) And Encourages Shareholders to Reach Out ACCESS Newswire
QUREuniQure N.V. Stock news uniQure: The Market Graded The Wrong Exam Seeking Alpha
QUREuniQure N.V. Legal uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation ACCESS Newswire
QUREuniQure N.V. Legal uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investments Newsfile Corp
QUREuniQure N.V. Legal Bronstein, Gewirtz & Grossman, LLC Encourages uniQure N.V. (QURE) Stockholders to Inquire about Securities Investigation ACCESS Newswire
QUREuniQure N.V. Legal Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against uniQure N.V. (QURE) And Encourages Investors to Reach Out ACCESS Newswire
QUREuniQure N.V. Stock news uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review Defense World
QUREuniQure N.V. Legal UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop Business Wire
QUREuniQure N.V. Stock news uniQure (NASDAQ:QURE) Stock Price Down 5.5% Following Analyst Downgrade Defense World
QUREuniQure N.V. Legal UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights GlobeNewsWire
QUREuniQure N.V. Stock news uniQure Plunges on Additional Data From Huntington's Disease Study Zacks Investment Research
QUREuniQure N.V. Stock news uniQure Stock Crashed on Its Huntington's Data. Wall Street's Price Target Says the Selloff Went Too Far 24/7 Wall Street
QUREuniQure N.V. Legal uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) PRNewsWire
QUREuniQure N.V. Stock news uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing Transcript Seeking Alpha
QUREuniQure N.V. Legal QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law Business Wire
QUREuniQure N.V. Legal QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C. GlobeNewsWire
DOW Stock news Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings Benzinga
QUREuniQure N.V. Stock news Uniqure Plummets 40% On Another Shocking Twist For Its Huntington's Drug Investors Business Daily
See more
FAQ

Questions about uniQure N.V.

What does uniQure N.V. do?
uniQure N.V. is a gene therapy company focused on developing treatments for patients with genetic and other devastating diseases. Its lead program is etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for hemophilia B. The company is also developing AMT-130, a gene therapy in Phase I/II clinical study for Huntington's disease; AMT-060, in Phase I/II clinical trial for hemophilia B; AMT-210 for Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical candidate for autosomal dominant Alzheimer's disease; and AMT-161 for amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
What is QURE's market cap?
uniQure N.V. (QURE) is a listed stock with a live quote. The latest market cap on this page is $1.7B.
Where is uniQure N.V. headquartered?
uniQure N.V. is headquartered in Amsterdam.
How do I get QURE news from the API?
Call GET /v1/news?tickers=QURE. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does QURE news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for QURE, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the QURE price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs